Iovance Biotherapeutics, Inc. IOVA
8.72 USD +0.70 (+8.67%)
Nov 3, 2026, 3:25 PM EST
8.15 Day range 8.80
1.76 52-week range 15.37
- YTD
- +219.23%
- 1 year
- +346.92%
News
benzinga.com UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $8 UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $7 to $8.
zacks.com Iovance Gears Up to Report Q3 Earnings: Here's What to Expect IOVA is poised for a Q3 earnings beat as Amtagvi sales drive revenue, Proleukin adds growth and pipeline progress draws investor attention.
benzinga.com Crude Oil Moves Lower; Caterpillar Shares Fall Following Q3 Results U.S. stocks fell Thursday, led by a 9% Caterpillar drop; Porch, Teladoc and Crocs surged, while oil, gold and silver declined.
seekingalpha.com Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc…
marketbeat.com Iovance's Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing Iovance Biotherapeutics NASDAQ: IOVA reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining…
zacks.com Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics License Application (sBLA) for Lifileucel in Non-Squamous mNSCLC in 2027KRAS Wild-Type Subgroup…
globenewswire.com Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned…
globenewswire.com Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on…
zacks.com Best Momentum Stocks to Buy for October 27th IOVA, MEI and PRMRF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27th, 2026.
zacks.com Why Investors Need to Take Advantage of These 2 Medical Stocks Now Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
zacks.com New Strong Buy Stocks for October 27th NTSK, PRMRF, IOVA, CAPL and MEI have been added to the Zacks Rank #1 (Strong Buy) List on October 27th, 2026.
globenewswire.com Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal…
benzinga.com Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026 50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026Unprecedented Efficacy in Both…
globenewswire.com Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026 50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both…- benzinga.com Iovance's Phase 2 Lifileucel Plus Pembrolizumab Delivers 62.5% ORR And 29.2% Complete Response Rate In Frontline Advanced Melanoma, With Median OS Not Yet Reached At 50.9 Months 62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 AnalysisMedian Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-upOral…
globenewswire.com Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma 62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral…
zacks.com These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
globenewswire.com Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026 Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously…
seekingalpha.com Undercovered Dozen: Hess Midstream, Iovance Biotherapeutics, Netlist, And More The Undercovered Dozen highlights 12 lesser-covered stocks from the past week on Seeking Alpha. This curated series aims to spark investment ideas and community discussion around overlooked equities.…
globenewswire.com Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering…
benzinga.com Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18 Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11 Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.
benzinga.com Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call Iovance Biotherapeutics (NASDAQ:IOVA) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…
defenseworld.net 55,275 Shares of Iovance Biotherapeutics, Inc. $IOVA Purchased by Corient Private Wealth LP Corient Private Wealth LP purchased a new stake in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) in the second quarter, according to its most recent disclosure with the Securities and Exchange…
benzinga.com Top 3 Health Care Stocks That May Collapse In Q4 Three healthcare stocks—Quantum-Si, Kodiak Sciences and Iovance—show overbought RSI readings above 80, warning momentum-focused investors.
seekingalpha.com Iovance: Buy Now Before Many Growth Catalysts Kick In Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline…
zacks.com These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
globenewswire.com Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on…- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18 Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $14 to $18.
benzinga.com Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On? Shares of Iovance Biotherapeutics are trading slightly lower Wednesday morning, taking a breather after Tuesday's surge which pushed the stock to a new 52-week high.
benzinga.com Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why These 5 Stocks Are on Investors' Radars Today FICO, IOVA, SDEV, CCL, MU were among the trending stocks on Tuesday, Sept. 29, 2026.- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance…
benzinga.com Crude Oil Down 1%; US Job Openings Fall In August U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.
benzinga.com HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20 HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $9 to $20.
benzinga.com CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow fell 100+ points; CarMax surged 9.7% on strong results, while Iovance, Carnival and others gained.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock…
- benzinga.com Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.
- benzinga.com Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15 Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $13 to $15.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com TD Cowen Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $10 TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.
benzinga.com Iovance Biotherapeutics Stock Is Trending Friday: What's Going On? Shares of Iovance Biotherapeutics are trending Friday morning after a momentum surge pushed the biotech stock to a new 52-week high.
benzinga.com Why Iovance Biotherapeutics Stock Hit 52-Week High Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.
benzinga.com UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7 UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $4 to $7.